<DOC>
	<DOCNO>NCT01246635</DOCNO>
	<brief_summary>The purpose clinical study demonstrate effectiveness safety Trufit CB ( Cartilage Bone ) implant treatment single , isolated cartilage defect knee compare Microfracture .</brief_summary>
	<brief_title>Smith &amp; Nephew 's European Trufit Study</brief_title>
	<detailed_description>315 subject , age 18 year old single , isolated cartilage defect knee randomize 1:1:1 ratio 1 3 treatment group : - Trufit CB Implant rehabilitation protocol ; - Trufit CB Implant rehabilitation protocol ; - Microfracture rehabilitation protocol Rehabilitation program may standard ( 6 week touch weight full weight bear ) accelerate ( 2 week touch weight full weight bearing )</detailed_description>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>Capable providing informed consent ; Eighteen ( 18 ) year older skeletally mature date study enrollment ; Willing able attend follow visit complete study relate procedure evaluation include , limited adhere rehabilitation protocol ; Single , isolated cartilage defect ( ICRS Grade III IV ) knee ( medial lateral femoral condyle trochlea ) ≥ 1cm2 ( 10 mm ) ≤ 2cm2 ( 20 mm ) area require maximum 2 implant ( randomize TRUFIT CB ) ; Note : Lesion size assess product long diameter perpendicular apply wide portion lesion . Candidate cartilage repair surgery result single , isolated symptomatic cartilage lesion ; Presents stable health time study enrollment ; BMI ≤ 32 . Female childbearing potential pregnant plan become pregnant course study ; History alcohol drug abuse ; Presents patellofemoral instability anatomical malalignment study knee ; Any diagnosis would preclude patient successfully complete study rehabilitation protocol ; Unable unwilling follow post operative procedure ( e.g . rehabilitation protocol ) ; Received one intraarticular steroid injection study knee within previous 3 month ; Presents ipsilateral hip disease , determine pain restrict range motion upon physical examination ; Treated either investigational device drug within one ( 1 ) month study enrollment , plan treated investigational device drug next 24 month ; Diagnosed rheumatoid arthritis , ankylose spondylitis ( Bechterew syndrome ) , calcium pyrophosphate dihydrate disease ( chondrocalcinosis ) ; History severe vascular neurological disease , uncontrolled diabetes , immunosuppressed ( e.g . HIV positive ) ; Musculoskeletal disease , include degenerative bone diseases osteochondritis dissecans osteonecrosis ; Pathologic condition bone ( e.g . osteoporosis , cystic change , hyperparathyroidism , Paget 's Disease , hypercalcemia , prolong use steroid ) ; Active infection , evidence thereof , lesion site ; Requires use medication ( ) treatment ( ) know effect bone metabolism ( e.g . bisphosphonates , chemotherapeutic immunosuppressive agent ) ; Requires concomitant osteotomy , partial lateral meniscectomy complete meniscectomy ; Note : Concomitant ACL reconstruction revision , well meniscal repair partial medial meniscectomy permit study protocol . Has undergone ACL reconstruction , osteotomy , chondral resurface procedure partial meniscectomy ( ≤ central third meniscus ) last year complete least 6 month rehabilitation since surgery ; Note : Patients undergone procedure within last year complete least 6 month rehabilitation eligible participate study . Any active , implanted medical device ( e.g . cochlear implant ) metallic implant ( dental work ) may interfere Magnetic Resonance Imaging ( MRI ) ; Any condition ( e.g . claustrophobia ) may interfere patient 's ability undergo MRI ; Diagnosis require placement active implant ( e.g . cardiac pacemaker , vagus nerve stimulator , etc . ) within next 24 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>